The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 62)
Research Grant, 2018
There is a pressing need for Parkinson's disease (PD) biomarkers -- objective measures of disease -- that will enable early and accurate diagnosis and allow to track disease progression and therapeutic improvement. We have developed a new mathematical method to characterize PD-related brain networks. This method is based on a mathematical analysis of data collected via resting sta...
Biomarkers Across Neurodegenerative Diseases, 2018
This study builds on two recent discoveries in neuroscience: first, the brain is organized in large-scale networks of nerve cells; and second, the clumps of alpha-synuclein, amyloid and tau -- proteins implicated in Parkinson's disease (PD) and Alzheimer's disease (AD) -- can spread from nerve cell to nerve cell, like infection.
Parkinson's and Alzheimer's affect diffe...
Researchers: Alain Dagher, MD
Improved Biomarkers and Clinical Outcome Measures, 2018
Does the Brain's Ability to Compensate for the Shortage of Dopamine Affect Parkinson's Disease Progression?
Parkinson's disease (PD) is a progressive disorder, but it is unclear what causes the gradual worsening of the symptoms over the years. It is also unknown why in some cases the disease progresses very rapidly while in others it has a mild course. Here we aim to investigate which brain mechanisms are involved in the gradual worsening of motor symptoms in PD. More specifically, we ai...
Researchers: Rick C.G. Helmich, MD, PhD
Research Grant, 2018
There is currently no effective imaging agent -- a chemical that reveals signs of disease -- that allows physicians to diagnose Parkinson's disease (PD) at an early stage, to monitor disease progression or to assess the effectiveness of treatments. We propose to develop and test an imaging agent that will reveal brain fibrils, the hallmark feature of Parkinson's visible on a magne...
Researchers: David S. Eisenberg, PhD
Improved Biomarkers and Clinical Outcome Measures, 2017
Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in Parkinson's Disease
This project will test a new idea for measuring the severity of Parkinson's disease (PD). The brain acts as if it can store each dose of levodopa (L DOPA) for a short period of time and lets it "leak" into the brain when needed. This levodopa reservoir appears to get "leakier" as PD progresses, contributing to a gradually briefer benefit from each dose of the drug. The new idea we...
Researchers: Kevin J. Black, MD